Black Book Research provides trustees with a practical, 129-page, vendor-agnostic governance manual, developed independently and not commissioned, sponsored, or affiliated with any health IT vendor or vendor-supported professional association, to clarify HIT priorities, educate new and existing board members, and strengthen independent oversight of 2026-2027 digital and IT budget approvals.
Read MoreConformity with stringent new EU regulations for medical devices confirmed
Allows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countries
Major milestone in international growth strategy
Crofelemer can potentially extend lives of MVID patients - infants and children who face the lethal natural history of the disease
Parenteral support reduction of up to 37% is groundbreaking; No approved treatments exist for MVID in any region
Read More
The acclaimed television series will highlight how LegalEASE is setting a new standard in legal benefits through innovation, education, and a national network of top-tier attorneys.
Read MorePDW is a leading manufacturer of combat robotics deployed by customers across every branch of the United States military
PDW's Drone Factory 01, a 90,000 sq. ft. manufacturing facility in Huntsville, Alabama has capacity to produce up to 100,000 NDAA-compliant advanced drone systems, valued at approximately $1 Billion, per year
Ondas' investment will be deployed to scale production, significantly increase engineering headcount, and secure supply of NDAA-compliant domestically sourced components
Read MoreNon-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility
Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028
Read MoreAnnounces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026
Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028
Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene
Further improves 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year on path to targeted cash breakeven in 2028
Read More
With elite training in endometriosis excision and a commitment to whole-body, multidisciplinary care, Dr. Chu expands ESSE's mission of integrative, patient-centered treatment for complex gynecologic conditions.
Read MoreTravel by David's offers personalized planning, exclusive perks, best-in-industry pricing and seamless booking for every life milestone
Read MoreFirst Infrastructure Platform for Verified Creators and Real-Time Content Provenance Launches Amid Unprecedented Surge in Deepfake Deception.
Read More